205 related articles for article (PubMed ID: 22930503)
1. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.
Luo Q; Zhong Y; Yang Y; Xiong Q; Hu Z; Lu W; Huang P; Zhang N
J Med Virol; 2012 Oct; 84(10):1558-61. PubMed ID: 22930503
[TBL] [Abstract][Full Text] [Related]
2. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D
J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E
J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
[TBL] [Abstract][Full Text] [Related]
4. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
5. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
[TBL] [Abstract][Full Text] [Related]
6. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
7. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
[TBL] [Abstract][Full Text] [Related]
8. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
[TBL] [Abstract][Full Text] [Related]
10. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
Selabe SG; Song E; Burnett RJ; Mphahlele MJ
J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
[TBL] [Abstract][Full Text] [Related]
11. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.
Salpini R; Svicher V; Cento V; Gori C; Bertoli A; Scopelliti F; Micheli V; Cappiello T; Spanò A; Rizzardini G; De Sanctis GM; Sarrecchia C; Angelico M; Perno CF
Antiviral Res; 2011 Nov; 92(2):382-5. PubMed ID: 21920388
[TBL] [Abstract][Full Text] [Related]
12. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
[TBL] [Abstract][Full Text] [Related]
13. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
Svicher V; Gori C; Trignetti M; Visca M; Micheli V; Bernassola M; Salpini R; Gubertini G; Longo R; Niero F; Ceccherini-Silberstein F; De Sanctis GM; Spanò A; Cappiello G; Perno CF
J Hepatol; 2009 Mar; 50(3):461-70. PubMed ID: 19041149
[TBL] [Abstract][Full Text] [Related]
14. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
Ogata N; Ichida T; Aoyagi Y; Kitajima I
Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
[TBL] [Abstract][Full Text] [Related]
15. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
[TBL] [Abstract][Full Text] [Related]
16. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy.
Lin CL; Chien RN; Hu CC; Lai MW; Yeh CT
J Antimicrob Chemother; 2012 Jan; 67(1):39-48. PubMed ID: 22001270
[TBL] [Abstract][Full Text] [Related]
17. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
18. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
[TBL] [Abstract][Full Text] [Related]
20. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
